

2023 US INCENTIVE **COMPENSATION BENCHMARKING STUDY**

OVERVIEW

Axtria collected and analyzed incentive plan and performance data from 25+ organizations for the 2022 plan year to develop a robust and holistic set of anonymized benchmarks representative of incentive practices across the industry.

SAMPLE SIZE

IC plans

out of the top 10

out of the top 20 life sciences


organizations

therapy areas

life sciences organizations

KEY INSIGHTS

IC PLAN COMPONENTS




Individual goal attainment is the most common IC plan component for HCP and Account teams. For Market Access teams, management by objectives (MBO) and team goals are the most prevalent IC plan components.



GOAL SETTING


- Brand sales history, market sales, and equal allocation are the most common goal-setting markers for HCP teams.
- Oncology and Rare Disease team goal models most commonly leverage brand sales history or brand trended sales to set territory-level goals with limited to no use of market data.





- period of 6 months or less for brands in the launch or growth phase of their lifecycle. For mature brands, longer historical baseline periods of more than 6 months are more commonly used to set goals.





plans to pay top performers for more complex specialties. Oncology and Rare Disease IC plans tend to provide a higher

OVERALL PAY CAP



having an overall pay cap of 3.5x of target pay or higher.

upside earnings potential to top performers, with most teams

Life sciences organizations have been aggressive in designing IC

Primary Care Oncology **Rare Disease Speciality HCP Teams HCP Teams HCP Teams HCP Teams**



Across all team types,

on average, >95% of the team is engaged by the IC plan (receiving non-zero earnings).

teams have higher meaningful engagement of ~90%. **Note:** Meaningful engagement is the percentage of representatives earning more than or equal to 75% of their IC target.

Meaningful engagement for HCP teams


is ~75%. Account and Market Access

for top and bottom performers than teams supporting more mature brands.

294% **Maximum Earnings 220**%

IC earnings by portfolio maturity of HCP teams

HCP teams supporting launch brands showed higher differentiation in IC payouts









life sciences industry. We combine industry knowledge, business process, and technology to help our clients make better data-driven decisions. AIM (Axtria Intel Monitor) is an engaging series of thought leadership that showcases Axtria's intelligence on therapy areas, industries, and topics relevant to life sciences.

Founded in 2010, Axtria is a global provider of cloud software and data analytics to the



facebook.com/Axtrialnc/

in linkedin.com/company/axtria o instagram.com/lifeataxtria/